| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.1 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.1 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.1 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | thapsigargin | GDSC1000 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |